Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Bull of the Day: CRISPR Therapeutics (CRSP)
06:46am, Monday, 11'th Dec 2023
CRISPR Therapeutics ( CRSP ) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old def
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
05:43am, Monday, 11'th Dec 2023
CRISPR Therapeutics received marketing approval from the U.S. Food and Drug Administration for its first drug, called Casgevy, on Dec. 8. Shares of CRISPR Therapeutics fell sharply in response to what
The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person
03:12pm, Saturday, 09'th Dec 2023
The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.
Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
08:06pm, Friday, 08'th Dec 2023
The FDA has granted approval to a CRISPR-based gene editing therapy for the first time in history, validating the approach. The therapy, called Casgevy, is approved to treat Sickle Cell Disease after
Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US
05:25pm, Friday, 08'th Dec 2023
Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced Friday that the Food and Drug Administration (FDA) gave them approval for use of the first-ever gene-editing therapy using CRISPR
FDA Approves First Crispr Treatment for Sickle Cell Disease
03:50pm, Friday, 08'th Dec 2023
A gene-editing therapy for sickle cell disease was approved by US regulators, a milestone for the DNA-modifying technology Crispr. Crispr Co-Inventor, 2020 Nobel Prize winner in chemistry, and Innovat
Patients describe Casgevy gene-editing treatment as a cure, says Vertex CEO Reshma Kewalramani
03:45pm, Friday, 08'th Dec 2023
Reshma Kewalramani, CEO of Vertex Pharmaceuticals, and CNBC's Angelica Peebles join 'Power Lunch' to discuss the latest FDA gene-editing treatment approval, drug pricing, and more.
Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln
01:59pm, Friday, 08'th Dec 2023
Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
12:03pm, Friday, 08'th Dec 2023
Crispr Therapeutics AG CRSP, -5.37% and Vertex Pharmaceuticals Inc. VRTX, -1.25% on Friday got U.S. regulatory approval for a treatment for sickle-cell disease based on the transformative gene-editing
US approves two gene therapies for sickle cell disease
11:21am, Friday, 08'th Dec 2023
The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.
U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease
11:19am, Friday, 08'th Dec 2023
Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
08:15am, Friday, 08'th Dec 2023
CRISPR Therapeutics could commercialize its first medicine in the U.S. very soon. Yet, it laid off a significant portion of its workforce in advance of that possibility.
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
09:10am, Thursday, 07'th Dec 2023
The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
05:30am, Thursday, 07'th Dec 2023
Vertex Pharmaceuticals is trying to commercialize its gene therapy exa-cel. Researchers found some disturbing evidence about certain possible side effects.
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
05:15am, Thursday, 07'th Dec 2023
Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.
